Rates and Predictors of Persistent LUTS Medication Use After Laser Enucleation of the Prostate

Key Points

• This research aims to identify the rates and predictors of persistent LUTS medication use after laser enucleation of the prostate.
• Participants underwent laser enucleation of the prostate (LEP) to treat LUTS.
• Evaluated preoperative medication use, specifically PDE-5-inhibitors, and assessed comorbidity burden.
• Follow-up period lasted 24 months to determine ongoing medication necessity.
• LUTS medication use decreased significantly after LEP, with only a minority requiring continued medication at 24 months.
• Preoperative PDE-5-inhibitor use was identified as an independent predictor of ongoing LUTS medication.
• Higher comorbidity burden also correlated with increased likelihood of persistent medication use.